Status:
TERMINATED
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
Lead Sponsor:
Genentech, Inc.
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy. Patients wil...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adult patients, ≥ 18 years of age
- Active rheumatoid arthritis
- Inadequate treatment with any DMARD other than methotrexate
- Exclusion criteria:
- Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis
- Concurrent treatment with any DMARD other than methotrexate
- Previous treatment with any cell-depleting therapies
- Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline
Exclusion
Key Trial Info
Start Date :
April 24 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2009
Estimated Enrollment :
314 Patients enrolled
Trial Details
Trial ID
NCT00673920
Start Date
April 24 2008
End Date
October 26 2009
Last Update
December 4 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.